share_log

Capital One Initiates Coverage On Heron Therapeutics With Overweight Rating, Announces Price Target of $6

Capital One Initiates Coverage On Heron Therapeutics With Overweight Rating, Announces Price Target of $6

Capital One以增持评级启动对Heron Therapeutics的报道,宣布目标股价为6美元
Moomoo 24/7 ·  04/23 07:14

Capital One analyst Tim Chiang initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Overweight rating and announces Price Target of $6.

Capital One分析师蒂姆·姜以增持评级开始对Heron Therapeutics(纳斯达克股票代码:HRTX)进行报道,并宣布目标股价为6美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发